Patents by Inventor Django Sussman

Django Sussman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220175947
    Abstract: The invention provides modified heavy chain constant regions including a cysteine at position 295 by EU numbering and optionally at position 239 by EU numbering. These cysteine residues provide sites for conjugation to a drug or label. When both cysteines are present in a normal heterodimeric antibody format, there are four such sites per molecule of antibody allowing a stoichiometry of one molecule of antibody to four of drug or label. Selection of the cysteine at position 295 with or without cysteine at position 239 is advantageous over cysteines at many other positions due to ease of expression, stability and cytotoxicity.
    Type: Application
    Filed: February 28, 2018
    Publication date: June 9, 2022
    Applicant: SEAGEN INC.
    Inventors: Andrew WAIGHT, Chris LEISKE, Travis BIECHELE, Django SUSSMAN, Patrick BURKE, Jocelyn LEISKE
  • Patent number: 11351269
    Abstract: Disclosed are antibodies, including antibody drug conjugates, that specifically bind to NTB-A. Also disclosed are methods for using the anti-NTB-A antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an NTB-A-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with NTB-A-expressing cells, such as multiple myeloma, non-Hodgkin lymphoma and acute myeloid leukemia.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: June 7, 2022
    Assignee: Seagen Inc.
    Inventors: Timothy Lewis, Lori Westendorf, Django Sussman, Che-Leung Law
  • Patent number: 11325980
    Abstract: The invention provides methods of treating a subject having or at risk of cancer by administering a LIV-1 antibody drug conjugate and a chemotherapeutic.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: May 10, 2022
    Assignee: SEAGEN INC.
    Inventors: Django Sussman, Fu Li, Ana Kostic
  • Patent number: 11319526
    Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: May 3, 2022
    Assignee: Seagen Inc.
    Inventors: Stephen C. Alley, Scott C. Jeffrey, Django Sussman, Dennis R. Benjamin, Brian Toki, Patrick J. Burke
  • Publication number: 20220025062
    Abstract: The invention provides humanized antibodies that specifically bind to BCMA. The antibodies are useful for treatment and diagnoses of various cancers and immune disorders as well as detecting BCMA.
    Type: Application
    Filed: June 25, 2021
    Publication date: January 27, 2022
    Applicant: SEAGEN INC.
    Inventors: Django Sussman, Maureen Ryan, Lori Westendorf, Michael Feldhaus
  • Publication number: 20210340260
    Abstract: The invention provides antibodies that specifically bind to integrin ?v?6. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting ?v?6.
    Type: Application
    Filed: January 8, 2021
    Publication date: November 4, 2021
    Applicant: Seagen Inc.
    Inventors: Maureen Ryan, Django Sussman
  • Patent number: 11078291
    Abstract: The invention provides humanized antibodies that specifically bind to BCMA. The antibodies are useful for treatment and diagnoses of various cancers and immune disorders as well as detecting BCMA.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: August 3, 2021
    Assignee: Seagen Inc.
    Inventors: Django Sussman, Maureen Ryan, Lori Westendorf, Michael Feldhaus
  • Publication number: 20210228676
    Abstract: The present disclosure relates, in general, to methods for treating LIV-1-expressing cancers comprising administering an anti-LIV-1 antibody drug conjugate (LIV-1-ADC) in combination with a PD-1 antagonist, such as an anti-PD-1 antibody.
    Type: Application
    Filed: December 9, 2020
    Publication date: July 29, 2021
    Inventors: Zejing Wang, Nicholas Choong, Django Sussman
  • Publication number: 20210128742
    Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD123 and conjugates thereof.
    Type: Application
    Filed: January 5, 2021
    Publication date: May 6, 2021
    Applicant: Seagen Inc.
    Inventors: May Kung Sutherland, Lori Westendorf, Django Sussman
  • Publication number: 20210047404
    Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically hind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33.
    Type: Application
    Filed: July 29, 2020
    Publication date: February 18, 2021
    Applicant: SEATTLE GENETICS, INC.
    Inventors: May Kung Sutherland, Maureen Ryan, Django Sussman, Patrick Burke, Scott Jeffrey
  • Patent number: 10912842
    Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD123 and conjugates thereof.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: February 9, 2021
    Assignee: Seattle Genetics, Inc.
    Inventors: May Kung Sutherland, Lori Westendorf, Django Sussman
  • Patent number: 10787514
    Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically hind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: September 29, 2020
    Assignee: SEATTLE GENETICS, INC.
    Inventors: May Kung Sutherland, Maureen Ryan, Django Sussman, Patrick Burke, Scott Jeffrey
  • Publication number: 20200165335
    Abstract: The invention provides humanized antibodies that specifically bind to LIV-1. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting LIV-1.
    Type: Application
    Filed: February 6, 2020
    Publication date: May 28, 2020
    Inventors: Maria Leia SMITH, Django SUSSMAN, William ARTHUR, Albina NESTEROVA
  • Publication number: 20200062857
    Abstract: The present invention provides variant target binding agents and methods relating to the use of such binding agents for the prophylaxis or treatment of cancers and immunological disorders. The variant target binding agent is conjugated to a therapeutic agent that exerts a cytotoxic, cytostatic, or immunomodulatory effect on target cells.
    Type: Application
    Filed: July 29, 2019
    Publication date: February 27, 2020
    Applicant: Seattle Genetics, Inc.
    Inventors: Paul Carter, Django Sussman
  • Publication number: 20200031938
    Abstract: The invention provides antibodies that specifically bind to integrin ?v?6. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting ?v?6.
    Type: Application
    Filed: September 30, 2019
    Publication date: January 30, 2020
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Maureen Ryan, Django Sussman
  • Publication number: 20200002431
    Abstract: The invention provides humanized antibodies that specifically bind to BCMA. The antibodies are useful for treatment and diagnoses of various cancers and immune disorders as well as detecting BCMA.
    Type: Application
    Filed: May 14, 2019
    Publication date: January 2, 2020
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Django Sussman, Maureen Ryan, Lori Westendorf, Michael Feldhaus
  • Publication number: 20190381171
    Abstract: Disclosed herein are methods of enhancing antibody-dependent cell cytotoxicity (ADCC) in a subject comprising administering to a subject in need thereof a therapeutically effective amount of an anti-BCMA antibody and an effective amount of T lymphocytes and/or NK cells expressing an antibody-coupled T-cell receptor (ACTR) construct, which may comprises an extracellular domain with affinity and specific for the Fc portion of an immunoglobulin molecule (Ig); a transmembrane domain; optionally one or more of co-stimulatory domains, and a cytoplasmic signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM).
    Type: Application
    Filed: February 16, 2018
    Publication date: December 19, 2019
    Applicant: UNUM THERAPEUTICS INC.
    Inventors: Heather HUET, Seth ETTENBERG, Django SUSSMAN, Tooba CHEEMA, Taylor HICKMAN, Katie O'CALLAGHAN, Maureen RYAN
  • Patent number: 10443035
    Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: October 15, 2019
    Assignee: Seattle Genetics, Inc.
    Inventors: Stephen C. Alley, Scott C. Jeffrey, Django Sussman, Dennis R. Benjamin, Brian Toki, Patrick J. Burke
  • Publication number: 20190276796
    Abstract: The invention provides methods and compositions for preparing antibodies and antibody derivatives with reduced core fucosylation.
    Type: Application
    Filed: May 16, 2019
    Publication date: September 12, 2019
    Inventors: Stephen C. ALLEY, Scott C. JEFFREY, Django SUSSMAN, Dennis R. BENJAMIN, Brian TOKI, Patrick J. BURKE
  • Patent number: RE48959
    Abstract: The invention provides humanized antibodies that specifically bind to LIV-1. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting LIV-1.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: March 8, 2022
    Assignee: SEAGEN INC.
    Inventors: Maria Leia Smith, Django Sussman, William Arthur, Albina Nesterova